XXXX resistance, @entity32 , and the @entity5710 .

@entity1 @entity32 @entity2289 @entity6 @entity5710 @entity731 @entity2690 @entity412 @entity164 @entity453 @entity6170 @entity413 @entity165 @entity1851
@entity164 2 @entity6 is associated with a marked increase in the incidence of @entity453 ( @entity453 ); however, the correlation between glycemia and @entity453 in @entity1 with @entity164 2 @entity6 is only modestly positive. This relatively weak association between glycemia and @entity453 in subjects with @entity6 may be caused by the existence of an atherogenic @entity5710 . In the San Antonio Heart Study, subjects who start with normal @entity413 tolerance and later develop @entity164 2 @entity6 have increased @entity412 levels, increased systolic blood pressure, and decreased levels of high-density lipoprotein @entity165 before the onset of @entity164 2 @entity6 . The basis for these atherogenic @entity5710 changes may be related to @entity2690 resistance rather than reduced @entity2690 secretion. Recently, interest has focused on a possible role of fibrinolysis and increased subclinical @entity32 , as determined by high-sensitivity @entity1851 ( @entity1851 ) levels. The @entity2690 Resistance @entity731 Study found that @entity2690 resistance, as determined by a frequently sampled @entity413 tolerance test, is significantly related to higher @entity1851 levels, higher fibrinogen, and higher @entity2289 ( @entity2289 ) levels. The investigators also have shown that high @entity2289 and @entity1851 levels are predictors of the development of @entity164 2 @entity6 . In addition, the @entity1 's Health Study has shown that high @entity1851 levels predict @entity164 2 @entity6 . @entity2690 -sensitizing interventions have been demonstrated to reduce these nontraditional risk factors. @entity6170 , an agent with @entity2690 -sensitizing properties, decreases @entity2289 and @entity1851 levels. Some of the adverse cardiovascular effects seen in @entity1 with @entity164 2 @entity6 may be reversed by @entity2690 -sensitizing agents.
